Malignant pleural mesothelioma: new treatments, new hopes? Source: Eur Respir J , 49 (3) 1700319; DOI: 10.1183/13993003.00319-2017 Year: 2017
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic Source: Eur Respir Rev 2015; 24: 115-131 Year: 2015
Immunotherapy for malignant pleural mesothelioma: ready for clinical practice? Source: International Congress 2016 – Immunotherapy: the lethal weapon against thoracic malignancies? Year: 2016
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma Source: Eur Respir J, 51 (5) 1701610; 10.1183/13993003.01610-2017 Year: 2018
Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? Source: Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017 Year: 2018
Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
A novel proteomic technique to identify new diagnostic biomarkers for malignant pleural mesothelioma: a feasibility study. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021
Treating mesothelioma in 2021: what is the role of surgery and immunotherapy? Source: Virtual Congress 2021 – Hot news from the pleura Year: 2021
Same meat, different gravy: ignore the new names of mycobacteria Source: Eur Respir J, 54 (1) 1900795; 10.1183/13993003.00795-2019 Year: 2019
Recent developments in the systemic treatment of malignant pleural mesothelioma: a light at the end of the tunnel! Source: International Congress 2019 – State of the art session: Thoracic oncology Year: 2019
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015
Multimodal management of malignant pleural mesothelioma: where are we today? Source: Eur Respir J 2014; 44: 754-764 Year: 2014
Keynote lecture: Introduction: Treatment options and tumour biology of malignant pleural mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011
Is there a role for closed pleural biopsy in the diagnosis of mesothelioma in the 21st century? Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010
Malignant mesothelioma: new treatment advances, including targeted therapies Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care Year: 2021
Combination immunotherapy in mesothelioma: managing expectations and new toxicities Source: Virtual Congress 2021 – Lung cancer grand round Year: 2021
Novel therapeutic strategies against malignant pleural mesothelioma by selumetinib-loaded targeted nanoparticles. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017
Novel approaches to ultrasonography of the lung and pleural space: where are we now? Source: Breathe, 13 (2) 100; 10.1183/20734735.004717 Year: 2017